BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy

To investigate at the population level the impact of BRCA1/BRCA2 gene alterations in male breast cancer, we analyzed a population-based series of 25 male breast cancer cases from Florence, Central Italy. We combined mutational screening with the study of germ-line allele transcript levels and of tum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2003-01, Vol.63 (2), p.342-347
Hauptverfasser: OTTINI, Laura, MASALA, Giovanna, PAGLIERANI, Milena, CAMA, Alessandro, BIANCHI, Simonetta, MARIANI-COSTANTINI, Renato, PALLI, Domenico, D'AMICO, Cristina, MANCINI, Biancamaria, SAIEVA, Calogero, ACETO, Gitana, GESTRI, Donella, VEZZOSI, Vania, FALCHETTI, Mario, DE MARCO, Manola
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 347
container_issue 2
container_start_page 342
container_title Cancer research (Chicago, Ill.)
container_volume 63
creator OTTINI, Laura
MASALA, Giovanna
PAGLIERANI, Milena
CAMA, Alessandro
BIANCHI, Simonetta
MARIANI-COSTANTINI, Renato
PALLI, Domenico
D'AMICO, Cristina
MANCINI, Biancamaria
SAIEVA, Calogero
ACETO, Gitana
GESTRI, Donella
VEZZOSI, Vania
FALCHETTI, Mario
DE MARCO, Manola
description To investigate at the population level the impact of BRCA1/BRCA2 gene alterations in male breast cancer, we analyzed a population-based series of 25 male breast cancer cases from Florence, Central Italy. We combined mutational screening with the study of germ-line allele transcript levels and of tumor-associated losses of heterozygosity. Screening by protein truncation test and single-strand conformational polymorphism assay, followed by sequencing, revealed 4 pathogenetic mutations (4 of 25 = 16%; 95% confidence interval, 5-37%), 1 in BRCA1 and 3 in BRCA2, including mutations recurring in Central Italy (BRCA1 3345delAG and BRCA2 6696delTC). The a priori probability of carrying a mutation, estimated using BRCAPRO software, showed a good agreement between expected and observed mutations (14% versus 16%). A 7-fold association between germ-line mutations and family history of breast-ovarian cancer emerged. To investigate associations between BRCA1/BRCA2 status and clinicopathological characteristics, we analyzed the histopathological and immunophenotypic parameters of the tumors. A significant association emerged between mutation carrier status and high histological grade (P = 0.02). Furthermore, one BRCA2 carrier was affected with Paget's disease, an extremely rare male breast cancer histotype. Overall, BRCA1/2 mutations were observed to be strongly associated with positive c-erbB-2 immunostaining (P = 0.004). To evaluate germ-line allele expression, we used primer extension assays targeting frequent BRCA1 and BRCA2 polymorphisms. A BRCA2 allele transcript imbalance was found in one of four heterozygotes tested, all of them negative for germ-line mutations. BRCA1 transcript imbalances were not detected in nine heterozygotes analyzed. Losses of heterozygosity at one or more of nine loci in the BRCA2 region were found in 8 of 22 tumors tested. Interestingly, a case that was negative for BRCA1/BRCA2 germ-line mutations and that had a priori mutation probability
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72988503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18946645</sourcerecordid><originalsourceid>FETCH-LOGICAL-h300t-e23c2b656f295984e280c8ab993781cb54d69138adcc5592dbbe03b0612c7a7f3</originalsourceid><addsrcrecordid>eNqFkEtLA0EQhAdRTIz-BZmL3hbmuTvjLQajgYAgel56ZmfJyr6cxyH_3k2MePRU3fTXRVFnaE4lV1khhDxHc0KIyqQo2AxdhfA5rZISeYlmlEnBC5XPUXh8Wy0phr7Ch4nhLkWIzdDjMGkKx0tM3eCx3YEHG51vQmxswE2PO2gdNt5BiNhCb53HD3iJx2FM7dElMxBcNXmlan942ERo99foooY2uJuTLtDH-ul99ZJtX583q-U223FCYuYYt8zkMq-ZlloJxxSxCozWU3RqjRRVrilXUFkrpWaVMY5wQ3LKbAFFzRfo_sd39MNXciGWXROsa1vo3ZBCWTCtlCT8X5AqLfJcyAm8PYHJdK4qR9904Pflb58TcHcCIFhoaz-V0oQ_TkjCONX8G1Bsfmc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18946645</pqid></control><display><type>article</type><title>BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>OTTINI, Laura ; MASALA, Giovanna ; PAGLIERANI, Milena ; CAMA, Alessandro ; BIANCHI, Simonetta ; MARIANI-COSTANTINI, Renato ; PALLI, Domenico ; D'AMICO, Cristina ; MANCINI, Biancamaria ; SAIEVA, Calogero ; ACETO, Gitana ; GESTRI, Donella ; VEZZOSI, Vania ; FALCHETTI, Mario ; DE MARCO, Manola</creator><creatorcontrib>OTTINI, Laura ; MASALA, Giovanna ; PAGLIERANI, Milena ; CAMA, Alessandro ; BIANCHI, Simonetta ; MARIANI-COSTANTINI, Renato ; PALLI, Domenico ; D'AMICO, Cristina ; MANCINI, Biancamaria ; SAIEVA, Calogero ; ACETO, Gitana ; GESTRI, Donella ; VEZZOSI, Vania ; FALCHETTI, Mario ; DE MARCO, Manola</creatorcontrib><description>To investigate at the population level the impact of BRCA1/BRCA2 gene alterations in male breast cancer, we analyzed a population-based series of 25 male breast cancer cases from Florence, Central Italy. We combined mutational screening with the study of germ-line allele transcript levels and of tumor-associated losses of heterozygosity. Screening by protein truncation test and single-strand conformational polymorphism assay, followed by sequencing, revealed 4 pathogenetic mutations (4 of 25 = 16%; 95% confidence interval, 5-37%), 1 in BRCA1 and 3 in BRCA2, including mutations recurring in Central Italy (BRCA1 3345delAG and BRCA2 6696delTC). The a priori probability of carrying a mutation, estimated using BRCAPRO software, showed a good agreement between expected and observed mutations (14% versus 16%). A 7-fold association between germ-line mutations and family history of breast-ovarian cancer emerged. To investigate associations between BRCA1/BRCA2 status and clinicopathological characteristics, we analyzed the histopathological and immunophenotypic parameters of the tumors. A significant association emerged between mutation carrier status and high histological grade (P = 0.02). Furthermore, one BRCA2 carrier was affected with Paget's disease, an extremely rare male breast cancer histotype. Overall, BRCA1/2 mutations were observed to be strongly associated with positive c-erbB-2 immunostaining (P = 0.004). To evaluate germ-line allele expression, we used primer extension assays targeting frequent BRCA1 and BRCA2 polymorphisms. A BRCA2 allele transcript imbalance was found in one of four heterozygotes tested, all of them negative for germ-line mutations. BRCA1 transcript imbalances were not detected in nine heterozygotes analyzed. Losses of heterozygosity at one or more of nine loci in the BRCA2 region were found in 8 of 22 tumors tested. Interestingly, a case that was negative for BRCA1/BRCA2 germ-line mutations and that had a priori mutation probability &lt;10% showed loss of heterozygosity at all three of the intragenic BRCA2 markers analyzed, which could be related to a somatic involvement of BRCA2. No losses of heterozygosity were detected at BRCA1. In conclusion, constitutional BRCA1/BRCA2 mutations accounted for 16% of the male breast cancer cases in this area of Central Italy. The detection of a BRCA2 germ-line transcript imbalance and of a somatic loss of BRCA2 among the cases that resulted negative for germ-line mutations suggests a role of this gene more relevant than indicated by conventional mutational analysis. A distinct pattern of characteristics indicative of aggressive behavior, including high-grade and c-erbB-2 expression, was evident in tumors from germ-line BRCA2 mutation carriers. This suggests that phenotypic characteristics may contribute to the identification of hereditary BRCA2-related male breast cancers and that these tumors might share a unique molecular pathway of cancer progression.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 12543786</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Alleles ; Biological and medical sciences ; BRCA1 Protein - biosynthesis ; BRCA1 Protein - genetics ; BRCA2 protein ; BRCA2 Protein - biosynthesis ; BRCA2 Protein - genetics ; Breast Neoplasms, Male - epidemiology ; Breast Neoplasms, Male - genetics ; Breast Neoplasms, Male - metabolism ; Breast Neoplasms, Male - pathology ; Genes, BRCA1 ; Genes, BRCA2 ; Germ-Line Mutation ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Italy - epidemiology ; Ki-67 Antigen - metabolism ; Loss of Heterozygosity ; Male ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Polymorphism, Genetic ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Tumors</subject><ispartof>Cancer research (Chicago, Ill.), 2003-01, Vol.63 (2), p.342-347</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14502319$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12543786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OTTINI, Laura</creatorcontrib><creatorcontrib>MASALA, Giovanna</creatorcontrib><creatorcontrib>PAGLIERANI, Milena</creatorcontrib><creatorcontrib>CAMA, Alessandro</creatorcontrib><creatorcontrib>BIANCHI, Simonetta</creatorcontrib><creatorcontrib>MARIANI-COSTANTINI, Renato</creatorcontrib><creatorcontrib>PALLI, Domenico</creatorcontrib><creatorcontrib>D'AMICO, Cristina</creatorcontrib><creatorcontrib>MANCINI, Biancamaria</creatorcontrib><creatorcontrib>SAIEVA, Calogero</creatorcontrib><creatorcontrib>ACETO, Gitana</creatorcontrib><creatorcontrib>GESTRI, Donella</creatorcontrib><creatorcontrib>VEZZOSI, Vania</creatorcontrib><creatorcontrib>FALCHETTI, Mario</creatorcontrib><creatorcontrib>DE MARCO, Manola</creatorcontrib><title>BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>To investigate at the population level the impact of BRCA1/BRCA2 gene alterations in male breast cancer, we analyzed a population-based series of 25 male breast cancer cases from Florence, Central Italy. We combined mutational screening with the study of germ-line allele transcript levels and of tumor-associated losses of heterozygosity. Screening by protein truncation test and single-strand conformational polymorphism assay, followed by sequencing, revealed 4 pathogenetic mutations (4 of 25 = 16%; 95% confidence interval, 5-37%), 1 in BRCA1 and 3 in BRCA2, including mutations recurring in Central Italy (BRCA1 3345delAG and BRCA2 6696delTC). The a priori probability of carrying a mutation, estimated using BRCAPRO software, showed a good agreement between expected and observed mutations (14% versus 16%). A 7-fold association between germ-line mutations and family history of breast-ovarian cancer emerged. To investigate associations between BRCA1/BRCA2 status and clinicopathological characteristics, we analyzed the histopathological and immunophenotypic parameters of the tumors. A significant association emerged between mutation carrier status and high histological grade (P = 0.02). Furthermore, one BRCA2 carrier was affected with Paget's disease, an extremely rare male breast cancer histotype. Overall, BRCA1/2 mutations were observed to be strongly associated with positive c-erbB-2 immunostaining (P = 0.004). To evaluate germ-line allele expression, we used primer extension assays targeting frequent BRCA1 and BRCA2 polymorphisms. A BRCA2 allele transcript imbalance was found in one of four heterozygotes tested, all of them negative for germ-line mutations. BRCA1 transcript imbalances were not detected in nine heterozygotes analyzed. Losses of heterozygosity at one or more of nine loci in the BRCA2 region were found in 8 of 22 tumors tested. Interestingly, a case that was negative for BRCA1/BRCA2 germ-line mutations and that had a priori mutation probability &lt;10% showed loss of heterozygosity at all three of the intragenic BRCA2 markers analyzed, which could be related to a somatic involvement of BRCA2. No losses of heterozygosity were detected at BRCA1. In conclusion, constitutional BRCA1/BRCA2 mutations accounted for 16% of the male breast cancer cases in this area of Central Italy. The detection of a BRCA2 germ-line transcript imbalance and of a somatic loss of BRCA2 among the cases that resulted negative for germ-line mutations suggests a role of this gene more relevant than indicated by conventional mutational analysis. A distinct pattern of characteristics indicative of aggressive behavior, including high-grade and c-erbB-2 expression, was evident in tumors from germ-line BRCA2 mutation carriers. This suggests that phenotypic characteristics may contribute to the identification of hereditary BRCA2-related male breast cancers and that these tumors might share a unique molecular pathway of cancer progression.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alleles</subject><subject>Biological and medical sciences</subject><subject>BRCA1 Protein - biosynthesis</subject><subject>BRCA1 Protein - genetics</subject><subject>BRCA2 protein</subject><subject>BRCA2 Protein - biosynthesis</subject><subject>BRCA2 Protein - genetics</subject><subject>Breast Neoplasms, Male - epidemiology</subject><subject>Breast Neoplasms, Male - genetics</subject><subject>Breast Neoplasms, Male - metabolism</subject><subject>Breast Neoplasms, Male - pathology</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Germ-Line Mutation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Italy - epidemiology</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Loss of Heterozygosity</subject><subject>Male</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Polymorphism, Genetic</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Tumors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLA0EQhAdRTIz-BZmL3hbmuTvjLQajgYAgel56ZmfJyr6cxyH_3k2MePRU3fTXRVFnaE4lV1khhDxHc0KIyqQo2AxdhfA5rZISeYlmlEnBC5XPUXh8Wy0phr7Ch4nhLkWIzdDjMGkKx0tM3eCx3YEHG51vQmxswE2PO2gdNt5BiNhCb53HD3iJx2FM7dElMxBcNXmlan942ERo99foooY2uJuTLtDH-ul99ZJtX583q-U223FCYuYYt8zkMq-ZlloJxxSxCozWU3RqjRRVrilXUFkrpWaVMY5wQ3LKbAFFzRfo_sd39MNXciGWXROsa1vo3ZBCWTCtlCT8X5AqLfJcyAm8PYHJdK4qR9904Pflb58TcHcCIFhoaz-V0oQ_TkjCONX8G1Bsfmc</recordid><startdate>20030115</startdate><enddate>20030115</enddate><creator>OTTINI, Laura</creator><creator>MASALA, Giovanna</creator><creator>PAGLIERANI, Milena</creator><creator>CAMA, Alessandro</creator><creator>BIANCHI, Simonetta</creator><creator>MARIANI-COSTANTINI, Renato</creator><creator>PALLI, Domenico</creator><creator>D'AMICO, Cristina</creator><creator>MANCINI, Biancamaria</creator><creator>SAIEVA, Calogero</creator><creator>ACETO, Gitana</creator><creator>GESTRI, Donella</creator><creator>VEZZOSI, Vania</creator><creator>FALCHETTI, Mario</creator><creator>DE MARCO, Manola</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20030115</creationdate><title>BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy</title><author>OTTINI, Laura ; MASALA, Giovanna ; PAGLIERANI, Milena ; CAMA, Alessandro ; BIANCHI, Simonetta ; MARIANI-COSTANTINI, Renato ; PALLI, Domenico ; D'AMICO, Cristina ; MANCINI, Biancamaria ; SAIEVA, Calogero ; ACETO, Gitana ; GESTRI, Donella ; VEZZOSI, Vania ; FALCHETTI, Mario ; DE MARCO, Manola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h300t-e23c2b656f295984e280c8ab993781cb54d69138adcc5592dbbe03b0612c7a7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alleles</topic><topic>Biological and medical sciences</topic><topic>BRCA1 Protein - biosynthesis</topic><topic>BRCA1 Protein - genetics</topic><topic>BRCA2 protein</topic><topic>BRCA2 Protein - biosynthesis</topic><topic>BRCA2 Protein - genetics</topic><topic>Breast Neoplasms, Male - epidemiology</topic><topic>Breast Neoplasms, Male - genetics</topic><topic>Breast Neoplasms, Male - metabolism</topic><topic>Breast Neoplasms, Male - pathology</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Germ-Line Mutation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Italy - epidemiology</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Loss of Heterozygosity</topic><topic>Male</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Polymorphism, Genetic</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OTTINI, Laura</creatorcontrib><creatorcontrib>MASALA, Giovanna</creatorcontrib><creatorcontrib>PAGLIERANI, Milena</creatorcontrib><creatorcontrib>CAMA, Alessandro</creatorcontrib><creatorcontrib>BIANCHI, Simonetta</creatorcontrib><creatorcontrib>MARIANI-COSTANTINI, Renato</creatorcontrib><creatorcontrib>PALLI, Domenico</creatorcontrib><creatorcontrib>D'AMICO, Cristina</creatorcontrib><creatorcontrib>MANCINI, Biancamaria</creatorcontrib><creatorcontrib>SAIEVA, Calogero</creatorcontrib><creatorcontrib>ACETO, Gitana</creatorcontrib><creatorcontrib>GESTRI, Donella</creatorcontrib><creatorcontrib>VEZZOSI, Vania</creatorcontrib><creatorcontrib>FALCHETTI, Mario</creatorcontrib><creatorcontrib>DE MARCO, Manola</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OTTINI, Laura</au><au>MASALA, Giovanna</au><au>PAGLIERANI, Milena</au><au>CAMA, Alessandro</au><au>BIANCHI, Simonetta</au><au>MARIANI-COSTANTINI, Renato</au><au>PALLI, Domenico</au><au>D'AMICO, Cristina</au><au>MANCINI, Biancamaria</au><au>SAIEVA, Calogero</au><au>ACETO, Gitana</au><au>GESTRI, Donella</au><au>VEZZOSI, Vania</au><au>FALCHETTI, Mario</au><au>DE MARCO, Manola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2003-01-15</date><risdate>2003</risdate><volume>63</volume><issue>2</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>To investigate at the population level the impact of BRCA1/BRCA2 gene alterations in male breast cancer, we analyzed a population-based series of 25 male breast cancer cases from Florence, Central Italy. We combined mutational screening with the study of germ-line allele transcript levels and of tumor-associated losses of heterozygosity. Screening by protein truncation test and single-strand conformational polymorphism assay, followed by sequencing, revealed 4 pathogenetic mutations (4 of 25 = 16%; 95% confidence interval, 5-37%), 1 in BRCA1 and 3 in BRCA2, including mutations recurring in Central Italy (BRCA1 3345delAG and BRCA2 6696delTC). The a priori probability of carrying a mutation, estimated using BRCAPRO software, showed a good agreement between expected and observed mutations (14% versus 16%). A 7-fold association between germ-line mutations and family history of breast-ovarian cancer emerged. To investigate associations between BRCA1/BRCA2 status and clinicopathological characteristics, we analyzed the histopathological and immunophenotypic parameters of the tumors. A significant association emerged between mutation carrier status and high histological grade (P = 0.02). Furthermore, one BRCA2 carrier was affected with Paget's disease, an extremely rare male breast cancer histotype. Overall, BRCA1/2 mutations were observed to be strongly associated with positive c-erbB-2 immunostaining (P = 0.004). To evaluate germ-line allele expression, we used primer extension assays targeting frequent BRCA1 and BRCA2 polymorphisms. A BRCA2 allele transcript imbalance was found in one of four heterozygotes tested, all of them negative for germ-line mutations. BRCA1 transcript imbalances were not detected in nine heterozygotes analyzed. Losses of heterozygosity at one or more of nine loci in the BRCA2 region were found in 8 of 22 tumors tested. Interestingly, a case that was negative for BRCA1/BRCA2 germ-line mutations and that had a priori mutation probability &lt;10% showed loss of heterozygosity at all three of the intragenic BRCA2 markers analyzed, which could be related to a somatic involvement of BRCA2. No losses of heterozygosity were detected at BRCA1. In conclusion, constitutional BRCA1/BRCA2 mutations accounted for 16% of the male breast cancer cases in this area of Central Italy. The detection of a BRCA2 germ-line transcript imbalance and of a somatic loss of BRCA2 among the cases that resulted negative for germ-line mutations suggests a role of this gene more relevant than indicated by conventional mutational analysis. A distinct pattern of characteristics indicative of aggressive behavior, including high-grade and c-erbB-2 expression, was evident in tumors from germ-line BRCA2 mutation carriers. This suggests that phenotypic characteristics may contribute to the identification of hereditary BRCA2-related male breast cancers and that these tumors might share a unique molecular pathway of cancer progression.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>12543786</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2003-01, Vol.63 (2), p.342-347
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_72988503
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Age Factors
Aged
Aged, 80 and over
Alleles
Biological and medical sciences
BRCA1 Protein - biosynthesis
BRCA1 Protein - genetics
BRCA2 protein
BRCA2 Protein - biosynthesis
BRCA2 Protein - genetics
Breast Neoplasms, Male - epidemiology
Breast Neoplasms, Male - genetics
Breast Neoplasms, Male - metabolism
Breast Neoplasms, Male - pathology
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
Italy - epidemiology
Ki-67 Antigen - metabolism
Loss of Heterozygosity
Male
Mammary gland diseases
Medical sciences
Middle Aged
Polymorphism, Genetic
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Tumors
title BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : A population-based study in Italy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRCA1%20and%20BRCA2%20mutation%20status%20and%20tumor%20characteristics%20in%20male%20breast%20cancer%20:%20A%20population-based%20study%20in%20Italy&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=OTTINI,%20Laura&rft.date=2003-01-15&rft.volume=63&rft.issue=2&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E18946645%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18946645&rft_id=info:pmid/12543786&rfr_iscdi=true